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Abstract
Anti-EGFR therapy appears to be a potential treatment option for squamous cell anal carcinoma (SCAC). KRAS mutation is a
rare event in SCAC, indicating the absence of the principal mechanism of resistance to this type of therapy. However, no
information is available from the literature regarding the status of BRAF or PIK3CA in this cancer type. We analysed KRAS,
BRAF and PIK3CA status in SCAC patients in relation to the clinical-pathological characteristics of patients and to the
presence of the human papilloma virus (HPV). One hundred and three patients were treated with the Nigro scheme for anal
cancer from March 2001 to August 2012. Fifty patients were considered for the study as there was insufficient paraffin-
embedded tumour tissue to perform molecular analysis the remaining 53. DNA was extracted from paraffin-embedded
sections. KRAS, BRAF and PIK3CA gene status and HPV genotype were evaluated by pyrosequencing. KRAS and BRAF genes
were wild-type in all cases. Conversely, PIK3CA gene was found to be mutated in 11 (22%) cases. In particular, 8 mutations
occurred in exon 9 and 3 in exon 20 of the PIK3CA gene. These findings suggest that SCAC could potentially respond to an
anti-EGFR drug. PIK3CA mutation may be involved in the process of carcinogenesis in some cases of SCAC.
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Introduction
Although anal carcinoma is not a common tumour, its
incidence has increased progressively in parallel with transmitted
viral infections. Infection from human papilloma virus (HPV) is
the main etiologic factor for anal cancer and a high percentage of
patients are HPV-positive [1]. Up until 20 or 30 years ago, surgery
was the standard treatment for this tumour, consisting in
abdominoperineal resection or Miles Operation. The overall 5-
year survival is around 50–70%.
In recent years, the therapeutic approach to anal cancer has
changed dramatically from demolitive surgery to conservative
treatment with radiochemotherapy. Today surgery is mainly used
for diagnostic purposes and/or as salvage treatment in locore-
gional failure after radiochemotherapy.
The first description of the use of radiochemotherapy goes back
to the 1970s when the Nigro regimen showed a high rate of
complete responses in patients undergoing surgery after preoper-
ative treatment with low doses of radiation (30 Gy) administered in
combination with 5-fluorouracil and mitomycin C. Treatment has
changed very little since then. Recently, a clinical response to anti-
EGFR drugs was observed in single patients [2,3] and in small case
series of patients [4], suggesting their potential effectiveness in this
type of cancer.
EGFR expression in anal carcinoma is observed in approxi-
mately 80–90% of cases [5–7]. Moreover, some studies have
demonstrated that KRAS mutations, the principal mechanism of
resistance to anti-EGFR therapy, are virtually absent in this
tumour [5–7]. Such information could represent an important
prerequisite for the use of anti-EGFR strategies. However, the
incidence of other gene alterations, e.g. BRAF and PIK3CA
mutations, involved in the response to anti-EGFR therapies in
colorectal cancer [8] has not been studied in anal carcinoma.
In the present study we set out to verify the incidence of KRAS,
BRAF and PIK3CA mutations in a series of patients with anal
carcinoma and analysed the association between these alterations
and the clinical-pathological characteristics of patients.
Patients and Methods
Patient Population
We retrospectively analysed 103 patients with SCAC consec-
utively treated with chemotherapy and radiotherapy at Istituto
Scientifico Romagnolo per lo Studio e la Cura dei Tumori in
Meldola (Italy) and the Medical Oncology Units of Faenza,
Ravenna and Macerata Hospitals (Italy) from March 2001 to
August 2012. There was insufficient paraffin-embedded tumour
tissue to perform molecular analysis in 53 cases. Our study thus
comprised 50 patients with stage I to IV invasive SCAC treated
with the Nigro regimen (radiation therapy with concurrent 5-
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fluorouracil and mitomycin C) for whom paraffin-embedded
tumour tissue was available.
According to TNM classification [9], 29 patients had early stage
SCAC (stage 1 or 2), 19 patients had stage 3 disease and 2 patients
had metastatic cancer. Thirty-four patients had a grade 1 or 2
tumour, and 16 had a grade 3 tumour. Forty-four patients were
HIV-negative and 6 were HIV-positive. Thirteen patients had
recurrent SCAC.
The study protocol was reviewed and approved by the Medical
Scientific Committee of IRST IRCCS, and written informed
consent was obtained from patients or from their next of kin for
the use of biological samples for research purposes.
Mutation Analysis
Formalin-fixed paraffin-embedded (FFPE) tumour blocks were
reviewed for quality and tumour content. For each case, an area
containing at least 50% of tumour cells was selected in
hematoxylin and eosin-stained sections, and corresponding 5-mM
sections were macrodissected and collected in specific tubes for
DNA extraction. Tumour cells were lysed in 50 mM of KCl,
10 mM of Tris-HCl pH 8.0, 2.5 mM of MgCl2 and Tween-20
(0.45%) in the presence of 1.25 mg/ml of proteinase K, overnight
at 56uC. Proteinase K was inactivated at 95uC for 10 minutes and
the samples were then centrifuged twice at 6000 rpm to eliminate
debris. DNA was purified using QIAamp DNA Micro kit (Qiagen,
Hilden, Germany) in accordance with the ‘‘Genomic DNA clean-
up’’ protocol. DNA quantity and quality were assessed by
Nanodrop (Celbio, Milan, Italy).
KRAS (exons 2 and 3), BRAF (exons 11 and 15) and PIK3CA
(exons 9 and 20) genes were analysed by pyrosequencing using 3
different kits: anti-EGFR MoAb response (KRAS status), anti-
EGFR MoAb response (BRAF status) and anti-EGFR MoAb
response (PIK3CA status) (Diatech Pharmacogenetics, Jesi, Italy),
according to the manufacturer’s instructions. Reactions were run
on a PyroMark Q96 ID system (Qiagen).
HPV detection
HPV DNA was detected in genomic tumour DNA using the
HPV sign kit (Diatech Pharmacogenetics), which allows for the
amplification and sequencing of a hypervariable region of a highly
conserved region of the HPV gene extracted from tumour tissue.
Specific genotypes were assigned by pyrosequencing using the
Pyromark Q96 ID system (Qiagen) which analyses and aligns the
determined sequence with the sequencing library supplied in the
kit.
Statistical Analyses
Progression-free survival (PFS) was calculated from the first day
of treatment to the date of the first observation of disease
progression or to the date of the last follow-up. Overall survival
(OS) was calculated from the first day of treatment to the date of
death due to any cause or to the date of the last follow-up. PFS,
OS and their 95% confidence intervals (95% CI) were estimated
using the Kaplan-Meier life-table method [10] and survival curves
were compared by the logrank test [11]. The association between
KRAS, BRAF and PIK3CA alteration/mutation and the clinical-
pathological characteristics of the patients was analysed by the chi-
square test.
Statistical significance was assumed for P,0.05 [12]. Statistical
analyses were carried out with SAS Statistical software (version
9.3, SAS Institute, Cary, NC).
Results
Fifty patients (19 males, 31 females) were evaluated. Median age
was 62 years (range, 37–87 years). Nineteen (38%) patients had
regional nodal involvement, 18 (36.0%) had stage 3–4 disease and
2 (4%) had distant metastases.
All patients had wild type KRAS (codons 12, 13, 61 and 146) and
BRAF (exons 11 and 15), whereas 11 (22%) had a mutation in the
PIK3CA gene. In particular, 8 had a PIK3CA mutation in exon 9
and 3 had a mutation in exon 20 (Table 1). The clinical
characteristics of patients are reported in Table 2. All patients
were HPV-positive; 46 (92%) had HPV type 16, one had an HPV-
16/18 co-infection and the other 3 patients had HPV type 31, 35
or 6.
At a median follow-up of 38 months (range, 2–138 months), 12
patients had died and 13 patients were in progression. Of these, 7
patients had locoregional failure and 6 had systemic failure. PFS
was 77% (95% CI 64–90) at one year and 72% (95% CI 57–85) at
3 years. The overall survival rate was 95% (95% CI 89–100) at 1
year and 81% (95% CI 67–94) at 3 years (Fig. 1). OS and PFS in
relation to the clinical-pathological characteristics of patients are
summarised in Tables 3 and 4, respectively.
No association was found between PIK3CA mutations and
clinical characteristics of patients. Moreover, no correlation was
found between PFS and OS (data not shown). Conversely, HPV-
16 was associated with a significantly longer PFS and a higher,
albeit not statistically significant, OS compared to the other HPV
genotypes (Fig. 2).
Discussion
Although anal cancer is considered a curable disease, around
20% of patients relapse and a further 30% undergo colostomy for
treatment-related toxicities. Treatment has essentially remained
the same for 30 years. In our study, PFS and OS were influenced
by tumour grade, primary tumour dimension and lymph node
status (Fig. 2), in agreement with data presented in the literature
[13]. Yhim et al. [14] analysed the correlation between HPV
infection and PFS and OS in 48 patients with anal carcinoma. In
the HPV-16-positive group, 4-year PFS and OS rates were 63.1%
(95% CI, 53.1–73.1) and 84.6% (95% CI, 76.2–93.0), respectively,
while 4-year PFS and OS rates in the HPV-16-negative group
were 15.6% (95% CI, 5.6–25.7) and 39.8% (95% CI, 26.1–53.4),
respectively. HPV-16-positive patients had significantly longer
PFS and OS than HPV-16-negative cases (PFS, P,0.001; OS,
P= 0.008). In our study, HPV-16 positive patients had a longer
PFS than those with other HPV genotypes, showing a trend
towards statistical significance (P= 0.061). Such a trend was not
Table 1. Results of PIK3CA mutations.
PIK3CA mutations No. mutated cases % Total cases (n =50)
All 11 22
Exon 9 8 16
E545K 5 10
E542K 2 4
Q546E 1 2
Exon 20 3 6
H1047L 2 4
H1047R 1 2
doi:10.1371/journal.pone.0092071.t001
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observed for OS (P= 0.747), even though HPV-16 positive
patients showed a longer OS than negative cases.
We did not observe mutations of the KRAS gene, in agreement
with the findings of other studies [5–7]. Moreover, no mutations of
the BRAF gene were detected. Conversely, 22% of patients were
found to have PIK3CA exon 9 and exon 20 mutations. No
association was found between PIK3CA mutations and prognosis.
Cetuximab (moAb anti-EGFR) represents a promising treatment
choice for anal carcinoma. Several studies on colorectal cancer
(CRC) have shown that KRAS gene mutations impair response to
the drug [15]. It has also been demonstrated that BRAF and
PIK3CA gene mutations in CRC may be associated with a worse
response to treatment and poorer prognosis [16]. Our study shows
that KRAS and BRAF are not mutated in anal carcinoma, whereas
PIK3CA, mutated in about 20% of cases, may represent a
mechanism of resistance to anti-EGFR treatment, such as
cetuximab. KRAS mutation appears to be a rare event in other
squamous cell tumours, such as head and neck cancer [17] and
cervical cancer [18]. However, the few studies published on BRAF
mutations in squamous cell carcinomas would seem to indicate a
low mutation rate [17]. Recently, some studies reported an
incidence of PIK3CA mutations in other squamous cell cancers
similar to that observed in our study. In particular, Lui and co-
workers found a PIK3CA mutation in 30.5% of head and neck
cancer patients who were sensitive to anti-mTOR treatment [19].
In a study by McIntyre and co-workers, about 20% of squamous
cervical cancer patients showed a PIK3CA mutation and these
patients had a better prognosis than those with wild-type tumours
[20]. These results, together with our findings, suggest that the
PIK3CA pathway could play an important role in the carcinogen-
esis of squamous cell carcinoma, especially those related to HPV
infection. A more complete understanding of this pathway could
facilitate the design of targeted therapy for these types of
malignancies.
Two interesting reports were recently published on the use of
cetuximab in anal cancer. The first was a phase I study of
cetuximab in combination with 5-FU, cisplatin and radiotherapy
for locally-advanced anal cancer. Of the 10 patients enrolled, all
completed full-dose radiotherapy, 9 were evaluable and 7 (78%)
achieved a complete response [21]. The second report focused on
the phase II ACCORD 16 study of cetuximab in combination
Table 2. Clinical characteristics of the patients with PIK3CA
mutation.
Exon 9 Exon 20
All patients 8 3
Gender
Male 2 1
Female 6 2
Age, years
,60 3 2
$60 5 1
Histological grade
Grade 1+/Grade 2 3 3
Grade 3 5 0
Tumour classification
1–2 5 2
3–4 3 1
Lymph node status
Negative 5 2
Positive 3 1
Stage
1 2 0
2 3 2
3 4 1
4 0 0
HIV status
Negative 5 3
Positive 3 0
HPV status
HPV-16 positive 8 3
HPV-16 negative 0 0
doi:10.1371/journal.pone.0092071.t002
Figure 1. Kaplan-Meier survival curves of (A) progression-free survival (PFS) and (B) overall survival (OS).
doi:10.1371/journal.pone.0092071.g001
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Figure 2. Kaplan-Meier survival curves of (A) progression-free survival (PFS) and (B) overall survival (OS) in relation to HPV-16
status.
doi:10.1371/journal.pone.0092071.g002
Table 3. Progression-free survival in relation to clinical-pathological characteristics of patients.
PFS No. of patients No. of events % 1-year PFS (95% CI) % 3-year PFS (95% CI) P
All patients 50 13 77 (64–90) 72 (57–85) -
Type of recurrence
Local 7 7 0 0 -
Distant 5 5 40 (0–83) 20 (0–55) 0.042
Histological grade
Grade 1+/Grade 2 34 5 86 (74–99) 82 (68–97) -
Grade 3 16 8 59 (33–84) 49 (21–76) 0.013
Tumour classification
1–2 27 3 87 (73–100) 87 (73–100) -
3–4 18 7 68 (45–91) 61 (36–86) 0.026
1–2–3 37 6 84 (71–97) 80 (66–94) -
4 8 4 58 (22–95) 58 (22–95) 0.031
Lymph node status
Negative 31 6 81 (67–96) 77 (60–93) -
Positive 19 7 69 (46–92) 61 (37–86) 0.068
Stage
1 8 0 100 100 -
2 21 4 79 (61–97) 79 (61–97) -
3 19 7 74 (53–96) 57 (31–84) -
4 2 2 0 0 ,0.0001
HIV status
Negative 44 12 74 (60–88) 71 (56–86) -
Positive 6 1 100 50 (0–100) 0.787
PIK3CA mutation
No 39 10 77 (63–91) 73 (57–88) -
Yes 11 3 78 (41–100) 65 (32–97) 0.889
HPV status
HPV-16 positive 45 10 82 (69–94) 75 (61–89) -
HPV-16 negative 5 3 40 (0–83) 40 (0–83) 0.061
doi:10.1371/journal.pone.0092071.t003
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with 5-FU, cisplatin and radiotherapy [22]. Of the 16 patients
included in this study, only 8 received the full planned treatment (6
cetuximab administrations and 2 5FU-cisplatin cycles. Accrual was
suspended after 10 serious adverse events (6 of which were
SUSARs) occurred in 7 of the first 10 patients enrolled. The
protocol was amended by decreasing the 5FU and cisplatin dose
was decreased and introducing mandatory intensity-modulated
radiation therapy. After the accrual of 6 additional patients, a
further 6 SAEs occurred in 5 patients. It was thus decided to close
the trial due to the high rate of toxicity. Further studies are needed
in the neoadjuvant setting to identify acceptable doses of
chemotherapy and radiotherapy and thus reduce the risk of
severe side-effects. Although it has also been hypothesized that
cetuximab could benefit patients with recurrent disease after
radiochemotherapy, few studies have been carried out in this area.
In conclusion, despite the relatively small sample size of our
study, we believe it is sufficient to demonstrate the presence or
absence of the mutations in question. Our results also suggest that
the use of the anti-EGFR drug could be used in anal carcinoma,
but further studies analysing the effect of this drug in relation to
molecular alterations are needed.
Acknowledgments
The authors would like to thank Ursula Elbling for editing the manuscript.
Author Contributions
Conceived and designed the experiments: ACG LC PU. Performed the
experiments: LC PU. Analyzed the data: ACG LC PU ES. Wrote the
paper: ACG MG EF ST AP LC PU. Conception and design of the work:
ACG DA. Acquisition of data: ACG MG EF ST AP AR. Analysis and
interpretation of data: ACG LC PU ES. Drafting the article: ACG MG EF
ST AP LC PU. Revising the article critically for important intellectual
content: WZ GLF. Final approval of the version to be published: ACG LC
PU MG EF ST ES AP WZ AR DA GLF.
References
1. Sˇkamperle M, Kocjan BJ, Maver PJ, Seme K, Poljak M (2013) Human
papillomavirus (HPV) prevalence and HPV type distribution in cervical, vulvar,
and anal cancers in Central and Eastern Europe. Acta Dermatovenerol Alp
Panonica Adriat 22: 1–5.
Table 4. Overall survival in relation to clinical-pathological characteristics of patients.
No. of patients No. of events % 1-year OS (95% CI) % 3-year OS (95% CI) P
All patients 50 12 95 (89–100) 81 (67–94) -
Type of recurrence
Local 7 7 71 (38–100) 18 (0–49) -
Distant 5 5 100 40 (0–83) 0.286
Histological grade
Grade 1 +/Grade 2 34 5 97 (91–100) 88 (74–100) -
Grade 3 16 7 93 (79–100) 64 (35–93) 0.014
Tumour classification
1–2 27 3 95 (87–100) 89 (75–100) -
3–4 18 6 94 (83–100) 70 (45–95) 0.054
1–2–3 37 6 97 (90–100) 84 (70–99) -
4 8 3 87 (65–100) 66 (25–100) 0.231
Lymphnode status
Negative 31 6 100 87 (73–100) -
Positive 19 6 87 (71–100) 70 (44–95) 0.075
Stage
1 8 0 100 100 -
2 21 4 100 81 (61–100) -
3 19 7 93 (81–100) 78 (55–100) -
4 2 1 50 (0–100) 50 (0–100) 0.0002
HIV status
Negative 44 11 95 (88–100) 79 (65–93) -
Positive 6 1 100 100 0.700
PIK3CA mutation
No 39 9 94 (87–100) 81 (66–97) -
Yes 11 3 100 75 (45–100) 0.706
HPV status
HPV-16 positive 45 10 91 (88–100) 82 (68–95) -
HPV-16 negative 5 2 100 75 (33–100) 0.538
doi:10.1371/journal.pone.0092071.t004
KRAS, BRAF and PIK3CA in SCAC
PLOS ONE | www.plosone.org 5 March 2014 | Volume 9 | Issue 3 | e92071
2. Barmettler H, Komminoth P, Schmid M, Duerr D (2012) Efficacy of cetuximab
in combination with FOLFIRI in a patient with KRAS wild-type metastatic anal
cancer. Case Rep Oncol 5: 428–433.
3. Bamba T, Suda T, Nakano M, Terashima T, Umezu H (2012) Pathologically
complete response for unresectable stage IV rectal cancer using systemic
chemotherapy with panitumumab - a case report. Gan To Kagaku Ryoho 39:
311–315.
4. Lukan N, Stro¨bel P, Willer A, Kripp M, Dinter D, et al. (2009) Cetuximab-based
treatment of metastatic anal cancer: correlation of response with KRAS
mutational status. Oncology 77: 293–299.
5. Paliga A, Onerheim R, Gologan A, Chong G, Spatz A, et al. (2012) EGFR and
K-ras gene mutation status in squamous cell anal carcinoma: a role for
concurrent radiation and EGFR inhibitors? Br J cancer 107: 1864–1868.
6. Zampino MG, Magni E, Sonzogni A, Renne G (2009) K-ras status in squamous
cell anal carcinoma (SCC): it’s time for target-oriented treatment? Cancer
Chemother Pharmacol 65: 197–199.
7. Van Damme N, Deron P, Van Roy N, Demetter P, Bols A, et al.(2010)
Epidermal Growth Factor Receptor and K-RAS status in two cohorts of
squamous cell carcinomas. BMC Cancer 10: 189.
8. Ulivi P, Capelli L, Valgiusti M, Zoli W, Scarpi E, et al. (2012) Predictive role of
multiple gene alterations in response to cetuximab in metastatic colorectal
cancer: a single center study. J Transl Med 10: 87.
9. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, et al. (2010) AJCC
Cancer Staging Manual (7th Edition). New York: Springer.
10. Kaplan EL, Meier P (2005) Non-parametric estimation from incomplete
observation. J Am Stat Assoc 24: 341–358.
11. Lawkess JS (1982) Statistical models and methods for life-time data. New York:
John Wiley and Sons 10: 316–317.
12. Cox DR (1972) Regression models and life tables. J Royal Stat Soc 34: 187–220.
13. Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, et al. (2007) Predictors and
patterns of recurrence after definitive chemoradiation for anal cancer.
Int J Radiat Oncol Biol Phys 68: 794–800.
14. Yhim HY, Lee NR, Song EK, Kwak JY, Lee ST, et al. (2011) The prognostic
significance of tumour human papillomavirus status for patients with anal
squamous cell carcinoma treated with combined chemoradiotherapy.
Int J Cancer 129: 1752–1760.
15. Lie`vre A, Bachet JB, Le Corre D, Boige V, Landi B, et al. (2006) KRAS
mutation status is predictive of response to cetuximab therapy in colorectal
cancer. Cancer Res 66: 3992–3995.
16. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, et
al. (2009) Multi-determinants analysis of molecular alterations for predicting
clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.
PLoS One 4: e7287.
17. Bruckman KC, Scho¨nleben F, Qiu W, Woo VL, Su GH (2010) Mutational
analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell
carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110: 632–637.
18. Pochylski T, Kwas´niewska A (2003) Absence of point mutation in codons 12 and
13 of K-RAS oncogene in HPV-associated high grade dysplasia and squamous
cell cervical carcinoma. Eur J Obstet Gynecol Reprod Biol 111: 68–73.
19. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, et al. (2013) Frequent
Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive
Biomarkers. Cancer Discov 3: 761–769.
20. McIntyre JB, Wu JS, Craighead PS, Phan T, Ko¨bel M, et al. (2013) PIK3CA
mutational status and overall survival in patients with cervical cancer treated
with radical chemoradiotherapy. Gynecol Oncol 128: 409–414.
21. Olivatto LO, Meton F, Bezerra M, Cardoso A, Araujo CM, et al. (2006) Phase I
study of cetuximab (CET) in combination with 5-fluorouracil (5-FU), cisplatin
(CP), and radiotherapy (RT) in patients with locally advanced squamous cell
anal carcinoma (LAAC). J Clin Oncol (suppl. 243) (abstr. 4609).
22. Deutsch E, Lemanski C, Pignon JP, Levy A, Delarochefordiere A, et al. (2013)
Unexpected toxicity of cetuximab combined with conventional chemoradiother-
apy in patients with locally advanced anal cancer: results of the UNICANCER
ACCORD 16 phase II trial. Ann Oncol 2013: 24:2834–2838.
KRAS, BRAF and PIK3CA in SCAC
PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e92071
